{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:31:08Z","timestamp":1793853068633,"version":"4.6.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018925","name":"Health Commission of Henan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010950","name":"Department of Science and Technology of Henan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jtho.2024.09.1385","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T04:05:23Z","timestamp":1725941123000},"page":"65-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["High-Dose Furmonertinib in Patients With EGFR-Mutated NSCLC and Leptomeningeal Metastases: A Prospective Real-World Study"],"prefix":"10.1016","volume":"20","author":[{"given":"Haiyang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuicui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2024.09.1385_bib1","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/S1470-2045(17)30689-7","article-title":"Leptomeningeal metastases in non-small-cell lung cancer","volume":"19","author":"Cheng","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2024.09.1385_bib2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cllc.2013.12.009","article-title":"Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era","volume":"15","author":"Riess","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2024.09.1385_bib3","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.jtho.2016.06.029","article-title":"Leptomeningeal metastases in patients with NSCLC with EGFR mutations","volume":"11","author":"Li","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.09.1385_bib4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/WCO.0000000000000393","article-title":"Leptomeningeal metastases of solid cancer","volume":"29","author":"Le Rhun","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.jtho.2024.09.1385_bib5","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ctrv.2016.12.006","article-title":"Leptomeningeal carcinomatosis in non-small cell lung cancer patients: a continuing challenge in the personalized treatment era","volume":"53","author":"Remon","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtho.2024.09.1385_bib6","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/neuonc\/nor121","article-title":"\u201cPulsatile\u201d high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer","volume":"13","author":"Grommes","year":"2011","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jtho.2024.09.1385_bib7","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.18632\/oncotarget.2886","article-title":"A\u00a0phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer","volume":"6","author":"Jackman","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2024.09.1385_bib8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/bjc.2017.394","article-title":"Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer","volume":"118","author":"Nanjo","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2024.09.1385_bib9","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study","volume":"38","author":"Yang","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2024.09.1385_bib10","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.24.00708","article-title":"Phase II efficacy and safety of 80 mg osimertinib in patients with leptomeningeal metastases associated with epidermal growth factor receptor mutation-positive non-small cell lung cancer (BLOSSOM)","volume":"42","author":"Park","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2024.09.1385_bib11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12916-023-02865-z","article-title":"Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies","volume":"21","author":"Hu","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.jtho.2024.09.1385_bib12","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jtho.2020.01.010","article-title":"Safety, clinical activity, and pharmacokinetics of Alflutinib (AST2818) in patients with advanced NSCLC with EGFR T790M mutation","volume":"15","author":"Shi","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 4","key":"10.1016\/j.jtho.2024.09.1385_bib13","doi-asserted-by":"crossref","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","article-title":"EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours","volume":"28","author":"Le Rhun","year":"2017","journal-title":"Annals Oncol"},{"key":"10.1016\/j.jtho.2024.09.1385_bib14","first-page":"484","article-title":"Leptomeningeal metastases: a RANO proposal for response criteria","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jtho.2024.09.1385_bib15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.lungcan.2018.08.017","article-title":"Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy","volume":"125","author":"Xu","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2024.09.1385_bib16","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.jtho.2021.04.018","volume":"16","author":"Fan","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.09.1385_bib17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41586-022-05580-6","article-title":"A\u00a0DNA methylation atlas of normal human cell types","volume":"613","author":"Loyfer","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.09.1385_bib18","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1158\/1078-0432.CCR-22-2177","article-title":"Genomic complexity predicts resistance to endocrine therapy and CDK4\/6 inhibition in hormone receptor-positive (HR+)\/HER2-negative metastatic breast cancer","volume":"29","author":"Davis","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.09.1385_bib19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2213-2600(20)30455-0","article-title":"Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study","volume":"9","author":"Shi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2024.09.1385_bib20","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2024.09.1385_bib21","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/JTO.0000000000000669","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis","volume":"10","author":"Liao","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.09.1385_bib22","doi-asserted-by":"crossref","first-page":"e1869","DOI":"10.1634\/theoncologist.2020-0640","article-title":"Erlotinib for non-small cell lung cancer with leptomeningeal metastases: a phase II study (LOGIK1101)","volume":"25","author":"Nosaki","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.jtho.2024.09.1385_bib23","first-page":"4177","article-title":"Cerebrospinal fluid penetration rate and efficacy of afatinib in patients with EGFR mutation-positive non-small cell lung cancer with leptomeningeal carcinomatosis: a multicenter prospective study","volume":"37","author":"Tamiya","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jtho.2024.09.1385_bib24","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00280-015-2759-y","article-title":"High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs","volume":"75","author":"Kawamura","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jtho.2024.09.1385_bib25","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/j.jtho.2022.09.037","article-title":"PP01.11 furmonertinib is an oral, irreversible, highly brain-penetrant pan-EGFR inhibitor with activity against classical and atypical EGFR mutations","volume":"18","author":"Musib","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.09.1385_bib26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.lungcan.2015.05.023","article-title":"Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: a retrospective cohort analysis","volume":"89","author":"Kuiper","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2024.09.1385_bib27","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/CAD.0000000000000489","article-title":"Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib","volume":"28","author":"Ariyasu","year":"2017","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.jtho.2024.09.1385_bib28","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(10)70034-6","article-title":"Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours","volume":"11","author":"Beauchesne","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2024.09.1385_bib29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2015.12.021","article-title":"Leptomeningeal metastasis: clinical experience of 519 cases","volume":"56","author":"Hyun","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2024.09.1385_bib30","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.1158\/1078-0432.CCR-17-0047","article-title":"Detection of driver and resistance mutations in leptomeningeal metastases of NSCLC by next-generation sequencing of cerebrospinal fluid circulating tumor cells","volume":"23","author":"Jiang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.09.1385_bib31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/ctrv.1999.0119","article-title":"Leptomeningeal carcinomatosis","volume":"25","author":"Grossman","year":"1999","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtho.2024.09.1385_bib32","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s13041-021-00886-4","article-title":"Integrated genomic and DNA methylation analysis of patients with advanced non-small cell lung cancer with brain metastases","volume":"14","author":"Xu","year":"2021","journal-title":"Mol Brain"},{"key":"10.1016\/j.jtho.2024.09.1385_bib33","doi-asserted-by":"crossref","first-page":"6168","DOI":"10.1158\/1078-0432.CCR-20-2081","article-title":"Biomarkers of osimertinib response in patients with refractory, EGFR-T790M-positive non-small cell lung cancer and central nervous system metastases: the Apollo study","volume":"26","author":"Xing","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.09.1385_bib34","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10555-015-9563-3","article-title":"Epigenetics in lung cancer diagnosis and therapy","volume":"34","author":"Mehta","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.jtho.2024.09.1385_bib35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/gutjnl-2011-301113","article-title":"Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer","volume":"62","author":"Ivanova","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.jtho.2024.09.1385_bib36","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canlet.2014.05.014","article-title":"SMYD2-dependent HSP90 methylation promotes cancer cell proliferation by regulating the chaperone complex formation","volume":"351","author":"Hamamoto","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jtho.2024.09.1385_bib37","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.neo.2020.01.001","article-title":"Epigenomic analysis of 5-hydroxymethylcytosine (5hmC) reveals novel DNA methylation markers for lung cancers","volume":"22","author":"Wang","year":"2020","journal-title":"Neoplasia"},{"key":"10.1016\/j.jtho.2024.09.1385_bib38","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.1038\/onc.2017.176","article-title":"A\u00a0DNA methylation map of human cancer at single base-pair resolution","volume":"36","author":"Vidal","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.jtho.2024.09.1385_bib39","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3389\/fgene.2019.00349","article-title":"Prognostic and predictive value of three DNA methylation signatures in lung adenocarcinoma","volume":"10","author":"Wang","year":"2019","journal-title":"Front Genet"},{"key":"10.1016\/j.jtho.2024.09.1385_bib40","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.21037\/tlcr.2019.12.09","article-title":"Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patients","volume":"8","author":"Xia","year":"2019","journal-title":"Transl Lung Cancer Res"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608642402269X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608642402269X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T13:59:53Z","timestamp":1736431193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155608642402269X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S155608642402269X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2024.09.1385","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-Dose Furmonertinib in Patients With EGFR-Mutated NSCLC and Leptomeningeal Metastases: A Prospective Real-World Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2024.09.1385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}